Docetaxel Rechallenge Shows Promise in Select Patients With mCRPC

BOSTON — For more than two decades, docetaxel has been a cornerstone in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Since its introduction in 2004, it has remained a foundational therapy, later joined by cabazitaxel—another taxane approved in 2010 for patients whose disease progresses after docetaxel.

Yet, a common clinical scenario has remained unresolved: What is the best next step for patients who stop docetaxel without disease progression?

A new retrospective cohort study conducted within the VA and published in JAMA Network Open, provides insight, suggesting that, for carefully selected patients, revisiting docetaxel may be a reasonable and potentially advantageous strategy.

“In clinical practice, some patients with metastatic castration resistant prostate cancer stop docetaxel for reasons other than disease progression, such as planned treatment breaks or cumulative toxicity,” said Karlynn N. Dulberger, PhD, associate director of data science at the VA Boston Healthcare System. “In these situations, clinicians vary in whether they pursue a docetaxel rechallenge or switch to cabazitaxel.”

“Because the comparative effectiveness of these two approaches had not been well defined, our study sought to address the uncertainty about which option might be most beneficial for this specific patient population,” she said.

The study analyzed 669 patients treated across the VA system between 2010 and 2023. All had received prior docetaxel and had not experienced disease progression during that treatment.¹

“Progression during the initial course of docetaxel generally indicates that the cancer has developed resistance mechanisms,” Dulberger explained. “In those cases, retreatment with docetaxel would not be expected to provide benefit and would expose patients to toxicity without therapeutic value.”

“To meaningfully evaluate a rechallenge strategy, it was essential to focus on patients who had not progressed during their first course and therefore might retain docetaxel sensitivity.”

The results showed a statistically significant survival advantage for docetaxel rechallenge. Median overall survival was 12.3 months compared with 9.6 months for cabazitaxel (hazard ratio 0.81; P = 0.04).

Secondary outcomes aligned with this finding. A higher proportion of patients receiving docetaxel rechallenge achieved a 90% or greater reduction in prostate-specific antigen (9.8% vs. 3.0%), and time to next treatment or death also was longer.

“Median overall survival differences between single agent therapies for mCRPC are typically modest,” Dulberger said. “The difference observed here falls within the range seen with other approved agents.”

“While individual patients may experience outcomes better or worse than the median, these results suggest that rechallenging with docetaxel may be a reasonable option for appropriately selected patients,” she said.

Cabazitaxel was developed to overcome taxane resistance, but its advantage may not apply equally in this setting.

“Our study specifically focused on patients who had not progressed during their initial course of docetaxel,” Dulberger told U.S. Medicine. “Because these individuals were more likely to retain sensitivity to docetaxel, it is plausible that rechallenging with docetaxel could perform favorably in this group.”

The analysis draws on nationwide VA data generated through a large-scale effort to better understand cancer outcomes in routine practice. While randomized trials remain the gold standard, they might not always be feasible in scenarios like this.

“Prospective randomized controlled trials remain the gold standard for establishing treatment efficacy,” Dulberger noted. “In circumstances where such trials are unlikely due to feasibility or resource constraints, real-world comparative effectiveness studies can supplement the evidence base by providing insights into how treatments perform in routine clinical practice.”

At the same time, the authors acknowledged the limitations of observational data. “Unmeasured or unavailable clinical factors, such as disease volume, symptom burden or other details not captured in the record may still have influenced which treatment was selected,” she said.

“For patients who previously responded to docetaxel, these retrospective findings suggest that a docetaxel rechallenge may be a reasonable option to consider alongside other available therapies,” Dulberger said. “Treatment sequencing should continue to be guided by clinical judgment, patient preferences, comorbidities and the broader body of evidence.”

Consistent with that perspective, Dulberger and her colleagues reported that docetaxel rechallenge “was associated with improved OS compared with cabazitaxel among patients who did not experience disease progression during prior docetaxel for mCRPC,” supporting its role as a treatment option in this setting.

 

1. Barata PC, Corrigan JK, La J, Culnan JM, et al. Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2026 Jan 2;9(1):e2551231.